Abbreviations & Acronyms AEG-1 = astrocyte elevated gene-1 DMSO = dimethyl sulfoxide EMT = epithelialmesenchymal transition MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide STAT3 = signal transducer and activator of transcription 3 Objectives: To determine the impact of astrocyte elevated gene-1 on the invasion and epithelial-mesenchymal transition of bladder cancer cells in vitro and metastasis in vivo. Methods: Gain-and loss-of-function studies were carried out to investigate the biological roles of astrocyte elevated gene-1 in bladder cancer cell invasion, epithelialmesenchymal transition and lung metastasis. The mechanism underlying the activity of astrocyte elevated gene-1 was examined. Results: Overexpression of astrocyte elevated gene-1 led to a significant increase in the invasive ability of UMUC3 and T24 bladder cancer cells in Matrigel invasion assays. In contrast, silencing of astrocyte elevated gene-1 restrained bladder cancer cell invasion. Overexpression of astrocyte elevated gene-1 downregulated E-cadherin and upregulated vimentin and Twist1, while silencing of astrocyte elevated gene-1 exerted an opposite effect. Mechanistically, astrocyte elevated gene-1 overexpression promoted the phosphorylation of signal transducer and activator of transcription 3 in bladder cancer cells. Treatment with WP1066, a specific signal transducer and activator of transcription 3 inhibitor, significantly abolished astrocyte elevated gene-1-induced invasion and epithelial-mesenchymal transition in UMUC3 cells. In vivo studies showed that astrocyte elevated gene-1 overexpression stimulated the growth of UMUC3 xenograft tumors and lung metastasis. Conclusions: Astrocyte elevated gene-1 shows the ability to promote bladder cancer metastasis, which is causally linked to induction of signal transducer and activator of transcription 3 activation and epithelial-mesenchymal transition. Therefore, targeting astrocyte elevated gene-1 might offer therapeutic benefits in treating metastatic bladder cancer.
Introduction AEG-1 (also known as MTDH) was originally identified in human fetal astrocytes as an inducible gene in response to HIV-1 and tumor necrosis factor-a. 1 Accumulating evidence has linked AEG-1 deregulation to tumor development. 2 AEG-1 is overexpressed in multiple cancer types, such as glioblastoma multiforme, 3 tongue squamous cell carcinoma 4 and gastric cancer. 5 AEG-1 can modulate cancer cell proliferation, invasion and metastasis. 6, 7 EMT is associated with the acquisition of increased invasive potential in epithelial cells. 8 This process is characterized by reduction of E-cadherin and elevation of vimentin expression. Several previous studies have documented that AEG-1 can facilitate the EMT of tumor cells. 4, 9 Bladder cancer is a common cancer of the genitourinary system and a leading cause of cancer-related deaths. 10 The prognosis of bladder cancer is poor as a result of highly invasive properties of tumor cells. 11 AEG-1 expression is raised in bladder cancer tissues relative to normal tissues, and serves as a poor prognostic factor for this malignancy. 12 In vitro loss-offunction studies show that AEG-1 knockdown induces apoptosis and suppresses anchorageindependent growth in bladder cancer cells. 13 Although AEG-1 is known to modulate cell proliferation and apoptosis in bladder cancer, its role in invasion and metastasis is still unknown.
In the present study, the impact of AEG-1 on the invasion and EMT of bladder cancer cells in vitro and lung metastasis in vivo was determined. Furthermore, the signaling pathway(s) involved in the activity of AEG-1 was investigated.
Methods

Cell culture
Human bladder cancer cell lines UMUC3 and T24 were obtained from the Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich).
Plasmid construction and transfection
The AEG-1-expressing plasmid and empty vector (pCMV6-Entry) was obtained from Origene (Rockville, MD, USA) and the AEG-1-targeting shRNA plasmid and scrambled shRNA plasmid from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cell transfection was achieved using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). To establish an AEG-1 stable cell line, UMUC3 cells were transfected with the pCMV6-AEG-1 plasmid and selected with G418 (600 lg/mL; Sigma-Aldrich) for 2 weeks. In some experiments, UMUC3 cells stably expressing AEG-1 cells (UMUC3-AEG-1) were incubated with WP1066 (1 lmol/L; EMD Millipore, Billerica, MA, USA) or DMSO (vehicle control) for 24 h before gene expression, viability and invasion analysis. 14 
Quantitative real-time polymerase chain reaction analysis
TRIzol reagent (Invitrogen) was used to extract total RNA from cells. cDNA was reverse transcribed from total RNA using the Superscript First-Strand Synthesis Kit (Takara, Dalian, China 
Matrigel invasion assay
The invasiveness of cancer cells was assessed using Matrigelcoated Boyden chambers in 24-well plates (BD Biosciences, Bedford, MA, USA). Briefly, cells suspended in serum-free medium (2 9 10 4 cells/well) were added to the upper chamber. The lower chamber was added with 10% fetal bovine serum in culture medium. After incubation for 24 h, inserts were stained with 1% crystal violet (Sigma-Aldrich). The number of invaded cells through Matrigel was counted.
Cell viability assay
Cell viability was detected using the MTT assay. Briefly, cells transfected with AEG-1-expressing plasmid, AEG-1 shRNA or corresponding controls were seeded in 96-well culture plates (8 9 10 3 cells/well) and cultured for 24-72 h. In some experiments, cells were incubated with WP1066 (1 lmol/L) or DMSO for 24 h before gene transfection. For assessment of viability, cells were incubated with 0.5 mg/mL MTT (Sigma-Aldrich) for 4 h at 37°C. Absorbance was measured at 570 nm.
Animal studies
UMUC3-AEG-1 and UMUC3-Mock cells (1 9 10 6 cells per mouse) were inoculated subcutaneously into the right flank of 5-week-old, male BALB/c nude mice (four mice per group). We measured the volume of xenograft tumors weekly for 4 weeks. After the last measurement, mice were killed. Tumor samples were subjected to western blot analysis or immunostained for phosphorylated STAT3 with an anti-phospho-STAT3 antibody (Cell Signaling Technology; 1:100 dilution). For metastatic studies, nude mice received injections of UMUC3-AEG-1 and UMUC3-Mock cells (2 9 10 6 cells per mouse) through the tail vein as previously described. 16 Mice were euthanized at 5 weeks after injection. Lungs were removed and the number of visible surface metastases was counted. Animal experiments were reviewed and approved by the Animal Care and Use Committee of Zhengzhou University (Zhengzhou, China).
Statistical analysis
Data are expressed as mean AE standard deviation. Statistical differences were analyzed by the Student's t-test or one-way analysis of variance. P < 0.05 shows statistical significance.
Results
AEG-1 enhances the invasiveness of bladder cancer cells
To clarify the role of AEG-1 in bladder cancer progression, we carried out gain-and loss-of-function studies (Fig. 1a) . AEG-1 overexpression enhanced UMUC3 cell proliferation from 48 h after seeding, whereas its silencing exerted an opposite effect on cell proliferation (Fig. 1b) . However, until 24 h after seeding, the proliferation of UMUC3 cells was not altered by either AEG-1 overexpression or knockdown. Similar findings were detected in T24 cells (data not shown).
In vitro Matrigel invasion assay showed that ectopic expression of AEG-1 significantly (P < 0.05) promoted the invasive ability of both UMUC3 and T24 cells (Fig. 1c) . In contrast, shRNA-mediated depletion of AEG-1 significantly (P < 0.05) inhibited bladder cancer cell invasion, compared with transfection with scrambled shRNA (Fig. 1d) . These results showed that AEG-1 contributes to the invasive phenotype of bladder cancer cells.
AEG-1 promotes EMT in bladder cancer cells
Next, we attempted to determine the effect of AEG-1 on EMT in bladder cancer cells. As shown in Figure 2a , UMUC3-AEG-1 cells displayed a morphological alteration to a spindle-like, fibroblastic phenotype. Measurement of key EMT markers, E-cadherin and vimentin, showed that E-cadherin was downregulated and vimentin was increased in UMUC3-AEG-1 cells (Fig. 2b) . Furthermore, the expression of Twist1, an EMT inducer, was pronouncedly induced by overexpression of AEG-1 (Fig. 2b) . In addition, AEG-1 silencing upregulated E-cadherin and downregulated Twist1 and vimentin in UMUC3 cells (Fig. 2c) . These results show that AEG-1 has the capacity to induce EMT in bladder cancer cells.
AEG-1 stimulates EMT and invasiveness by inducing STAT3 activation in bladder cancer cells
Next, we sought to determine the signaling pathway(s) involved in the pro-invasive activity of AEG-1. As shown in Figure 3 , AEG-1 overexpression noticeably enhanced the phosphorylation of STAT3 in UMUC3 cells, compared with control cells. However, the phosphorylation status of several other signaling molecules, including ERK, mTOR and b-catenin, was not altered by AEG-1 in UMUC3 cells (data not shown). To address the hypothesis that activation of STAT3 signaling is required for the pro-invasive activity of AEG-1, we inhibited STAT3 activation through a specific chemical inhibitor, WP1066. Treatment with WP1066 significantly impaired the phosphorylation level of STAT3 in UMUC3-AEG-1 cells (Fig. 3) .
Transwell invasion assay showed that the number of invaded cells was significantly reduced in the presence of WP1066 (Fig. 4a) . To exclude the possibility that the reduction in invaded cell number was a result of inhibition of cell viability, we examined the effect of WP1066 on the viability of UMUC3-AEG-1 cells by MTT assay. The result showed that WP1066 did not affect cell viability (Fig. 4b) . Additionally, we checked the effect of pharmacological inhibition of STAT3 signaling on AEG-1-induced EMT. As shown in 
AEG-1 promotes tumorigenesis and lung metastasis by bladder cancer cells in vivo
Having identified the oncogenic role of AEG-1 in vitro, we next validated its role in bladder cancer growth and metastasis in mouse models. UMUC3-AEG-1 and UMUC3-Mock cells were inoculated into nude mice to form subcutaneous xenograft tumors. Overexpression of AEG-1 led to a significant (P < 0.05) increase in tumor volume (Fig. 5a ) and weight ( Fig. 5b) , compared with control tumors. Western blot analysis of xenograft tumors showed that AEG-1-overexpressing tumors had a higher level of phosphorylated STAT3 protein than vector controls (Fig. 5c ). Immunohistochemistry confirmed a significant enhancement of STAT3 phosphorylation in the xenograft tumors formed by AEG-1-overexpressing cells (P < 0.05; Fig. 5d ).
To test whether AEG-1 can promote bladder cancer metastasis, UMUC3-AEG-1 and UMUC3-Mock cells were transplanted to nude mice through the tail vein. The number of metastatic foci on the surface of the lungs was significantly increased in the AEG-1 overexpression group relative to the control group (Fig. 5e) . Collectively, these results show that AEG-1 augments the proliferative and metastatic ability of bladder cancer cells in vivo.
Discussion
Compelling evidence shows that AEG-1 plays an oncogenic role in many cancer types. For example, AEG-1 knockdown leads to suppression of the invasive ability of glioblastoma cells. 3 Overexpression of AEG-1 facilitates metastasis of tongue squamous cell carcinoma. 4 A previous study provided evidence that AEG-1 is required for the growth, migration and survival of bladder cancer cells in vitro. 13 Concordantly, our data showed that silencing of AEG-1 restrained the invasion of bladder cancer cells through Matrigel. In contrast, overexpression of AEG-1 promoted bladder cancer cell invasion. EMT is regarded as a key event in cancer cell invasion and metastasis. 8 Reversal of EMT either by genetic or chemical approaches can block bladder cancer metastasis. 17, 18 Notably, the present data showed that AEG-1 overexpression accelerated EMT in bladder cancer cells. Taken together, AEG-1 contributes to the invasive phenotype of bladder cancer cells through induction of EMT.
Twist1 is a well-defined inducer of EMT and serves as a potential therapeutic target for metastatic bladder cancer. 19 Of note, we found that AEG-1 had the capacity to upregulate Twist1 in bladder cancer cells, which provides an explanation for the promotion of EMT by AEG-1. STAT3 is an important transcription factor controlling Twist1 transcription, which can directly bind to the promoter of Twist1. 20 It has been documented that silencing of STAT3 impairs transforming growth factor-b1-induced expression of Twist1 in prostate cancer cells. 20 Another study reported that activation of STAT3/Twist1 signaling contributes to gastric cancer growth and metastasis. 21 In bladder cancer, the STAT3/Twist1 axis is also involved in tumor cell invasion and metastasis. 22 Having identified the induction of Twist1 by AEG-1, we explored the signaling pathways involved in this process. We found that AEG-1 overexpression remarkably promoted the phosphorylation of STAT3 in bladder cancer cells. In agreement with the present findings, exogenous AEG-1 has been shown to trigger STAT3 activation in hypopharyngeal cancer cells. 23 AEG-1-deficient hepatocytes show a marked reduction in STAT3 phosphorylation, highlighting the importance of AEG-1 in the activation of STAT3 signaling. These studies, combined with the present results, suggest that AEG-1 overexpression evokes the activation of STAT3/Twist1 axis in bladder cancer cells, thus contributing to the aggressive phenotype. In support of this hypothesis, chemical inhibition of STAT3 was noted to decrease the invasive ability of AEG-1-overexpressing bladder cancer cells. Furthermore, inactivation of STAT3 reversed AEG-1-mediated EMT in bladder cancer cells, as evidenced by increased E-cadherin expression and reduced vimentin and Twist1 expression.
In line with in vitro studies, we found that AEG-1 overexpression facilitates bladder cancer growth and lung metastasis in mouse models. Additionally, enforced expression of AEG-1 led to an enhancement of STAT3 activation in UMUC3 subcutaneous xenograft tumors. The in vivo data further confirmed the oncogenic role of AEG-1 in bladder cancer development and progression. Consistent with our observations, the prometastatic activity of AEG-1 has also been described in tongue squamous cell carcinoma, 4 hepatocellular carcinoma 24 and lung cancer. 25 In conclusion, the present data show that AEG-1 contributes to bladder cancer growth and metastasis through induction of EMT. Activation of STAT3/Twist1, at least partially, accounts for the aggressive phenotype of bladder cancer cells induced by AEG-1 overexpression. These results provide insights into the molecular basis of AEG-1-driven malignancy and suggest AEG-1 as a potential therapeutic target for bladder cancer. 
